PD1/PD-L1blockers trigger metastasesDrug Developers dealing with PD1-PDL1 checkpoint inhibitors must consider new safety problems associated with the hyped cancer meds. more ➔
EIB incentivises bioeconomy investmentsThe European Investment Bank (EIB) has issued its first Sustainability Awareness Bond worth €500m to support investments into water projects – health and nutrition to follow. more ➔
New antibiotics on the block Around 300 international AMR experts met at ESCMID-ASM drug development conference in Lisbon to discuss the latest progress in the field. more ➔
Adaptimmune raises US$100mOxford-based Adaptimmune Therapeutics plc has raised US$100m in a registered direct offering of American Depositary Shares (ADS). more ➔
CAR-Ts: Novartis wins UKThe NHS England announces it will reimburse Novartis’ CAR-T cell therapy Kymriah as treatment for children with B cell acute lymphoblastic leukemia (ALL) that are refractory, in relapse post-transplant … more ➔
Evox raises €37m in Series B roundExosome drug delivery specialist Evox Therapeutics Ltd has closed a €37.1m (£35.5m) Series B financing round led by Redmile Group and significant contributions from GV (Google Ventures) … more ➔
Sanofi gets the EU’s ok for caplacizumabThe EU approved Sanofi’s Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday. more ➔
Cancer drug cures orphan disease skin damage An FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report. more ➔
Germany to pump €1bn into breakthrough innovationGermany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into p … more ➔
Urovant Sciences licenses OAB gene therapyUrovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations’ gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral … more ➔
